471 filings
Page 5 of 24
6-K
rkhic htqi7q6snhy2m
9 Aug 22
Inmagene and HUTCHMED Announce First Participant in Global Phase I Trial of IMG-004
6:21am
6-K
j712 mjob
8 Aug 22
HUTCHMED Announces that Fruquintinib Global Phase III FRESCO-2 Study Has Met Its Primary Endpoint in Metastatic Colorectal Cancer
6:24am
6-K
btzm8r0al3wu rm5h
1 Aug 22
HUTCHMED Reports 2022 Interim Results and Provides Business Updates
7:33am
6-K
vfq rmsdanqkx4
1 Aug 22
Current report (foreign)
6:53am
UPLOAD
7yyplbfh3
28 Jul 22
Letter from SEC
12:00am
CORRESP
6xjchoqvutnih
25 Jul 22
Correspondence with SEC
12:00am
UPLOAD
4iu99
21 Jul 22
Letter from SEC
12:00am
6-K
0qiuh6grs9wf5qp9a
15 Jul 22
Current report (foreign)
6:26am
6-K
reuv1 ecn98w
13 Jul 22
HUTCHMED Highlights First Presentation of Results of the SAVANNAH Global Phase II Trial of Savolitinib plus TAGRISSO® at the 2022 WCLC Annual Meeting
7:19am
6-K
juz3dxzr mad5ije7e6n
6 Jul 22
Inmagene and HUTCHMED Announce First Participants in Global Phase I Trial of IMG-007
6:15am
6-K
2nimt4rv jly3sxp8vn
30 Jun 22
Current report (foreign)
6:08am
6-K
z6qps0hrq9h70i3
29 Jun 22
Current report (foreign)
6:27am
6-K
f0qa75
27 Jun 22
HUTCHMED to Announce 2022 Half-Year Financial Results
6:20am
CORRESP
xn0va2
8 Jun 22
Correspondence with SEC
12:00am
6-K
7khnvtupm14mhqjhd9zq
1 Jun 22
HUTCHMED Announces TAZVERIK® Approved to be Used in Hainan Pilot Zone in China
6:25am
UPLOAD
z4x12muyajk
26 May 22
Letter from SEC
12:00am
6-K
04e2yldf18bi7
24 May 22
Grant of Awards under Long Term Incentive Plan and Share Options under Share Option Scheme
6:22am
6-K
orb2l6 iw1f1m
16 May 22
Appointment of Non–Executive Director
7:24am
6-K
2brk89qpecg es
2 May 22
Current report (foreign)
6:57am
6-K
rjutgl3 h6po9x
27 Apr 22
Current report (foreign)
9:33am